Biocon Rallies 5% On Novel Therapy Launch For Hepatitis C
Shares in Biocon surged 5.70 per cent after the company introduced an advanced novel therapy CIMIVIR-L for the treatment of Hepatitis C in India.
The stock was last trading higher by 5.70 per cent on the NSE at Rs 567. "The introduction of CIMIVIR-L will strengthen Biocon's current portfolio of verilogy products," the company said in a release to the bourses.
"It is estimated that nearly one lakh people die annually in India from HCV infection and co-morbidities. CIMIVIR-L is indicated for Hepatitis-C Genotype 1 patients who account for ~25% of the total estimated HCV patient population of 18 million in the country," the company said in a release.
GoodReturns.in